Drug Development Programs

Research Pipeline

Please contact us to discuss collaborative development and co-investment opportunities in the CNS and oncology/immunology space.  

 

Our current pipeline of compounds include:

MD 354:

  • Small molecule with a novel, first-in-class non-opioid mechansim of action for the treatment of neuropathic and chronic pain 
  • (Stage: Lead compound, available for partnering or out-license)

MD 22:

  • Novel small molecule anti-inflammatory compound for the treatment of lower back pain 
  • (Stage: in preclinical development, available for partnering) 

MD 401B:

  • Vectorized vaccine for the canine osteocarcinoma 
  • (Stage: in regulatory approval, available for partnering)

MD 401A:

  • Vectorized vaccine for the human osteocarcinoma 
  • (Stage: in preclinical development, available for partnering) 

MD 402:

  • Novel strategy for treatment of cancer 
 
 

    Collaboration Opportunities:

    • Preclinical Drug Development
    • Senerga® Phenotypic Screening 
    • In-and-Out Licensing Programs
    Inno

    Learn how the new InnovX® platform closes the gap between preliminary, early stage and industry relevant life science product research discoveries by academic institute researchers...and more. 

    Download now! 

    Screen_Shot_2016-06-24_at_12.51.24_PM.png